Loss of oligodendrocytes in multiple sclerosis (MS) leads to demyelination and axonal dysfunction and transection. Myelin repair, or remyelination, not only restores proper axonal conduction, but also protects axons from degeneration. Oligodendrocytes are myelin-producing cells and are generated from oligodendrocyte progenitor cells (OPCs). Although spontaneous production of oligodendrocytes and consequent remyelination do occur in early phases of MS, the efficiency decreases over time as the disease progresses. Therapeutic interventions to stimulate oligodendrocyte production and remyelination efficiency are likely to reduce disease progression and neurological disability.
Renovo offers several cell-based assays to identify and evaluate compounds for potential remyelination therapies for MS and other myelin-related diseases. Unique features of these assays include:
- Stringent protocols to generate relatively homogeneous (>95% pure NG2+) populations of mouse OPCs.
- OPCs derived from PLP-EGFP transgenic mice are used to increase the throughput and robustness of the assays.
- Automated quantitative image analyses allow relatively high throughput and unbiased results.
Our assays include: